Literature DB >> 16630294

Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.

Hideo Kurokawa1, Min Zhang, Shinobu Matsumoto, Yoshihiro Yamashita, Toshiko Tanaka, Koichi Takamori, Kaori Igawa, Maho Yoshida, Hiroshi Fukuyama, Tetsu Takahashi, Sumio Sakoda.   

Abstract

BACKGROUND: Although many histopathological characteristics of oral squamous cell carcinoma (O-SCC) have been identified as prognostic factors, no factor is completely accurate and unequivocal. This study evaluated the association between the loss of syndecan-1 expression and the histological grade of malignancy at the deep invasive front in O-SCC.
METHODS: The expression of syndecan-1 at the invasive tumor front of O-SCC was examined immunohistochemically using archived tissue from 72 cases. The mean age of the patients was 62.5 years (range: 23-90 years) and the male-female ratio was 1.3:1 (41 men, 31 women). There were 26, 24, 11, and 11 cases classified as stages I-IV respectively. The correlation between the intensity of syndecan-1 immunostaining and the clinicopathological factors, especially the histological grade of malignancy at the deep invasive front (invasive front grade) was analyzed.
RESULTS: Of the 72 cases, seven (9.7%), 29 (40.3%), 36 (50.0%) showed strong, intermediate, and weak or negative syndecan-1 staining respectively. There were significant differences between syndecan-1 expression and prognosis, differentiation, and pattern of invasion at the deep invasive front. Moreover, the invasive front grade scores, based on the intensity of syndecan-1 staining, were 5.6 +/- 1.0, 8.0 +/- 2.1, and 10.2 +/- 2.3 points with strong, intermediate, and weak or negative intensity respectively; and the difference was significant (P < 0.0001). Patients with intermediate or strong intensity for syndecan-1 had significantly better prognoses than did those with negative or weak intensity (P = 0.0138).
CONCLUSION: This study demonstrated that the reduced expression of syndecan-1 seems to be a useful marker of histological malignancy at the deep tumor invasive front and may be a useful prognostic factor in O-SCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630294     DOI: 10.1111/j.1600-0714.2006.00412.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  15 in total

Review 1.  Targeting syndecan-1: new opportunities in cancer therapy.

Authors:  Zecheng Yang; Shuaitong Chen; Haoqiang Ying; Wantong Yao
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-18       Impact factor: 5.282

2.  Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma.

Authors:  Yong-Quan Chu; Zai-Yuan Ye; Hou-Quan Tao; Yuan-Yu Wang; Zhong-Sheng Zhao
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

3.  Sdc1 negatively modulates carcinoma cell motility and invasion.

Authors:  Tohru Ishikawa; Randall H Kramer
Journal:  Exp Cell Res       Date:  2009-12-28       Impact factor: 3.905

4.  Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.

Authors:  Anna Farnedi; Silvia Rossi; Nicoletta Bertani; Mariolina Gulli; Enrico Maria Silini; Maria Teresa Mucignat; Tito Poli; Enrico Sesenna; Davide Lanfranco; Lucio Montebugnoli; Elisa Leonardi; Claudio Marchetti; Renato Cocchi; Andrea Ambrosini-Spaltro; Maria Pia Foschini; Roberto Perris
Journal:  BMC Cancer       Date:  2015-05-03       Impact factor: 4.430

Review 5.  Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.

Authors:  Tünde Szatmári; Rita Ötvös; Anders Hjerpe; Katalin Dobra
Journal:  Dis Markers       Date:  2015-09-01       Impact factor: 3.434

6.  Immunohistochemical analysis of syndecan-1 in leukoplakia and oral submucous fibrosis.

Authors:  Sushant S Kamat; G S Kumar; Ajit V Koshy
Journal:  Dent Res J (Isfahan)       Date:  2013-05

Review 7.  Molecular changes in invasive front of oral cancer.

Authors:  Mohit Sharma; Parul Sah; Sonal Soi Sharma; Raghu Radhakrishnan
Journal:  J Oral Maxillofac Pathol       Date:  2013-05

Review 8.  Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Sathyen A Prabhu; Matthew Gliksman; Betty Tai; Ahmet Hatipoglu; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2015-10-06

9.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

10.  Novel processed form of syndecan-1 shed from SCC-9 cells plays a role in cell migration.

Authors:  Annelize Z B Aragão; Marília Belloni; Fernando M Simabuco; Mariana R Zanetti; Sami Yokoo; Romênia R Domingues; Rebeca Kawahara; Bianca A Pauletti; Anderson Gonçalves; Michelle Agostini; Edgard Graner; Ricardo D Coletta; Jay W Fox; Adriana F Paes Leme
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.